September 16, 2024 04:25 AM EDTUpdated 06:37 AM
R&D
Pharma
Coronavirus

In sur­prise, study sug­gests Covid mR­NA vac­cines may boost can­cer im­munother­a­py ef­fi­ca­cy

Ryan Cross

Senior Science Correspondent

The mR­NA-based Covid vac­cines used by hun­dreds of mil­lions of peo­ple may pro­vide an un­ex­pect­ed ben­e­fit to some can­cer pa­tients, sig­nif­i­cant­ly im­prov­ing sur­vival when giv­en …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

Pfiz­er part­ners with two more Flag­ship biotechs on obe­si­ty, can­cer

When gen­er­a­tive AI meets the FDA: First dig­i­tal health ad­comm kicks off dis­cus­sion

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times